Duncker Streett & Co. Inc. Has $9.10 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Duncker Streett & Co. Inc. has reduced its holdings in Thermo Fisher Scientific by 7.2%, now holding a position worth approximately $9.1 million.
• Thermo Fisher Scientific reported a quarterly earnings per share of $5.36, exceeding analysts' expectations and showing a revenue increase of 2.9% year-over-year.
• Analysts have set a consensus price target of $589.10 for Thermo Fisher Scientific, with an average rating of "Moderate Buy" from fifteen analysts.

Duncker Streett & Co. Inc. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,435 shares of the medical research company's stock after selling 1,750 shares during the quarter. Thermo Fisher Scientific comprises about 1.7% of Duncker Streett & Co. Inc.'s holdings, making the stock its 14th largest position. Duncker Streett & Co. Inc.'s holdings in Thermo Fisher Scientific were worth $9,096,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of TMO. Vanguard Group Inc. increased its stake in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after purchasing an additional 230,382 shares in the last quarter. Amundi increased its stake in Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after purchasing an additional 168,197 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after acquiring an additional 115,463 shares during the period. Pictet Asset Management Holding SA lifted its holdings in Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after purchasing an additional 193,378 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after purchasing an additional 329,974 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.1%

TMO opened at $525.08 on Wednesday. The company has a market capitalization of $198.28 billion, a PE ratio of 30.37, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a 50-day simple moving average of $491.00 and a two-hundred day simple moving average of $448.20.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period last year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last 90 days. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TMO shares. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Weiss Ratings reissued a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Tuesday. HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $589.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.